Sonnet BioTherapeutics, Inc. logo

Sonnet BioTherapeutics, Inc.

SONNET BioTherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://sonnetbio.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1 Duncan Drive, NJ, 08512
Cranbury
United States
Email
Contact Number
+1 609-375-2227

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sonnet-biotherapeutics-inc.” connections=”true” suffix=””]

SONNET BioTherapeutics leverages a scaffold based on proprietary albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. Its proprietary TriDENT_ Discovery Platform, derived from the three core attributes, which work together for the Discovery of Enhanced Novel Therapeutics (DENT).
(1). Single-Chain Antibody (ScFV) Based. (2). Albumin Binding Domain (ABD); scFV that binds Human Serum Albumin (HSA).
(3). Recombinant Human (Hu) Proteins.